ArriVent BioPharma (AVBP) Income Statement (2023 - 2026)
Income Statement report data from Mar 31, 2023 to Mar 31, 2026 for ArriVent BioPharma (AVBP).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and COGS | |||||||||||||
Total Revenue | 2.79M (-14.94%) | 3.28M (-1.80%) | 3.34M (+50.45%) | 2.22M (-6.72%) | 2.38M (-22.48%) | 3.07M (-16.35%) | 3.67M (-3.93%) | 3.82M (+17.18%) | 3.26M (-38.02%) | 5.26M | - | - | - |
Operating Expenses | |||||||||||||
Research And Development | 38M (+16.94%) | 32M (0.00%) | 32M (+16.05%) | 28M (-54.77%) | 61M (+204.02%) | 20M (+0.35%) | 20M (-7.76%) | 22M (+28.27%) | 17M (-15.14%) | 20M (+40.13%) | 14M (-29.86%) | 20M (+98.83%) | 10M |
Selling General And Administrative | 8.49M (+27.67%) | 6.65M (+8.13%) | 6.15M (+4.24%) | 5.90M (+7.66%) | 5.48M (+54.80%) | 3.54M (-14.49%) | 4.14M (+5.61%) | 3.92M (+5.95%) | 3.70M (+18.97%) | 3.11M (+27.46%) | 2.44M (+9.42%) | 2.23M (+14.95%) | 1.94M |
Operating Expenses | 46M (+18.78%) | 39M (+1.30%) | 38M (+13.98%) | 34M (-49.65%) | 67M (+181.61%) | 24M (-2.15%) | 24M (-5.72%) | 26M (+24.33%) | 21M (-10.60%) | 23M (+38.28%) | 17M (-25.95%) | 23M (+85.54%) | 12M |
Operating Income | |||||||||||||
Operating Income | -46.11M (+18.78%) | -38.82M (+1.30%) | -38.32M (+13.98%) | -33.62M (-49.65%) | -66.77M (+181.73%) | -23.70M (-2.19%) | -24.23M (-5.72%) | -25.70M (+24.33%) | -20.67M (-10.60%) | -23.12M (+38.28%) | -16.72M (-25.95%) | -22.58M (+85.54%) | -12.17M |
Ebit | -46.11M (+18.78%) | -38.82M (+1.30%) | -38.32M (+13.98%) | -33.62M (-49.65%) | -66.77M (+181.73%) | -23.70M (-2.19%) | -24.23M (-5.72%) | -25.70M (+24.33%) | -20.67M (-10.60%) | -23.12M (+38.28%) | -16.72M (-25.95%) | -22.58M (+85.54%) | -12.17M |
EBITDA | -43.32M (+21.89%) | -35.54M (+1.60%) | -34.98M (+11.40%) | -31.40M (-51.23%) | -64.39M (+212.12%) | -20.63M (+0.34%) | -20.56M (-5.99%) | -21.87M (+25.55%) | -17.42M (-17.79%) | -21.19M (+47.15%) | -14.40M (-33.24%) | -21.57M (+77.24%) | -12.17M |
Other Income / Expenses | |||||||||||||
Interest Income | - | - | - | - | - | -10.75M | 3.67M (-3.93%) | 3.82M (+17.18%) | 3.26M | -3.33M | 2.32M (+127.45%) | 1.02M | - |
Net Interest Income | - | - | - | - | - | -10.75M | 3.67M (-3.93%) | 3.82M (+17.18%) | 3.26M | -3.33M | 2.32M (+127.45%) | 1.02M | - |
Net Income | |||||||||||||
Net Income From Continuing Operations | -43.32M (+21.89%) | -35.54M (+1.60%) | -34.98M (+11.40%) | -31.40M (-51.23%) | -64.39M (+212.12%) | -20.63M (+0.34%) | -20.56M (-5.99%) | -21.87M (+25.55%) | -17.42M (-17.79%) | -21.19M (+47.15%) | -14.40M (-33.24%) | -21.57M (+77.24%) | -12.17M |
Net Income | -43.32M (+21.89%) | -35.54M (+1.60%) | -34.98M (+11.40%) | -31.40M (-51.23%) | -64.39M (+212.12%) | -20.63M (+0.34%) | -20.56M (-5.99%) | -21.87M (+25.55%) | -17.42M (-17.79%) | -21.19M (+47.15%) | -14.40M (-33.24%) | -21.57M (+77.24%) | -12.17M |
Comprehensive Income Net Of Tax | -43.60M (-73.75%) | -166.08M (+377.93%) | -34.75M (+10.67%) | -31.40M (-51.08%) | -64.19M (-20.46%) | -80.70M (+292.51%) | -20.56M (-5.99%) | -21.87M (+25.55%) | -17.42M (-74.87%) | -69.33M | - | - | - |